The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $152.92 per unit over the past year.
Market view
glecaprevir and pibrentasvir · Tablet, Film Coated
5 marketed package NDCs · 2 active manufacturers
Most dispensed: 40 mg; 100 mg · Tablet, Film Coated · #4 cartons/carton / 7 blister pack in 1 carton / 3 tablet, film coated in 1 blister pack · 40 mg; 100 mg · Tablet, Film Coated · #4 cartons/carton / 7 dose pack in 1 carton / 3 tablet, film coated in 1 dose pack · 40 mg; 100 mg · Tablet, Film Coated · #84 tablet, film coateds/bottle
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $152.92 · middle half $152.92–$152.92 · full range $152.92–$152.92 · 3 products · 2 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for glecaprevir and pibrentasvir, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- MavyretSep 2, 2026Mfr exitedAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretSep 2, 2026Mfr exitedAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretAug 26, 2026Mfr enteredAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretAug 26, 2026Mfr enteredAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretAug 19, 2026Price downNADAC $153.03829 → $152.92388 per unit (-0.07%)
- MavyretAug 19, 2026Price downNADAC $153.03829 → $152.92388 per unit (-0.07%)
- MavyretAug 19, 2026Price downNADAC $153.03829 → $152.92388 per unit (-0.07%)
- MavyretJul 29, 2026Mfr exitedAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretJul 29, 2026Mfr exitedAbbVie Inc. · glecaprevir and pibrentasvir
- MavyretJul 22, 2026Price downNADAC $153.05412 → $153.03829 per unit (-0.01%)
Same drug class
Other molecules FDA puts in Hepatitis C Virus NS3/4A Protease Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Glecaprevir and pibrentasvir in shortage right now?
- No. FDA does not currently list Glecaprevir and pibrentasvir in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Glecaprevir and pibrentasvir?
- 2 companies have marketed Glecaprevir and pibrentasvir in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Glecaprevir and pibrentasvir cost?
- The typical pharmacy pays about $152.92 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.